REG - Creo Medical Group - Result of Placing

Creo MedicalAnnouncement

Today 10:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260522:nRSV4711Fa&default-theme=true

RNS Number : 4711F  Creo Medical Group PLC  22 May 2026

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR
INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE
REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD
CONSTITUTE A BREACH OF THE RELEVANT SECURITIES LAWS OF SUCH JURISDICTION.
PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.

 

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES AND DOES NOT CONSTITUTE AN OFFER
IN RESPECT OF ANY SECURITIES OF CREO MEDICAL GROUP PLC AND NEITHER THIS
ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, FORMS OR IS INTENDED TO FORM
THE BASIS FOR ANY INVESTMENT DECISION IN RESPECT OF CREO MEDICAL GROUP PLC OR
OTHER EVALUATION OF ANY SECURITIES OF CREO MEDICAL GROUP PLC OR ANY OTHER
ENTITY AND SHOULD NOT BE CONSIDERED AS A RECOMMENDATION THAT ANY INVESTOR
SHOULD SUBSCRIBE FOR OR PURCHASE ANY SUCH SECURITIES.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE UK
VERSION OF THE MARKET ABUSE REGULATION (EU NO. 596/2014) AS IT FORMS PART OF
UNITED KINGDOM DOMESTIC LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT
2018 ("UK MAR").

 

For immediate release

 

22 May 2026

Creo Medical Group plc

 

Result of Placing

 

Creo Medical Group plc (AIM: CREO), the medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients (the "Company" or "Creo" and, together with its subsidiary
undertakings, the "Group"), announces that, further to the announcement made
earlier today regarding the Placing (the "Launch Announcement"), it has raised
gross proceeds of £5.5 million by way of a placing of  36,666,664 new
ordinary shares of 0.1 pence each (the "Ordinary Shares") in the capital of
the Company (the "Placing Shares") at a price of 15 pence per Placing Share
(the "Issue Price").

 

The Issue Price represents a premium of approximately 31.9 per cent. to the
closing middle market price of 11.4 pence per Existing Ordinary Share on 21
May 2026, being the latest practicable date prior to the publication of the
Launch Announcement.

 

Allocations in the Placing will be confirmed to Placees as soon as practicable
today.

 

Shore Capital Stockbrokers Limited ("Shore Capital" or the "Bookrunner") is
acting as sole bookrunner in connection with the Placing.

 

Craig Gulliford, Chief Executive Officer of Creo Medical, said:

 

"We are very pleased to have received this strong support from investors for
our business and strategy.

 

"The Placing, alongside the other strategic funding initiatives we announced
this morning, strengthens the Group's balance sheet and positions Creo to
capitalise on the strong recent commercial and strategic momentum across our
business.

 

"We are seeing strong growth for our products and believe there is a
substantial opportunity as we expand the commercialisation of our product
portfolio and integrate our advanced energy technology into a wide range of
surgical platforms and robotics."

 

Capitalised terms used in this announcement (this "Announcement") have the
meanings given to them in the Launch Announcement, unless the context provides
otherwise.

 

Directors' participation in the Placing and Related Party Transactions

 

The following directors of the Company (the "Directors") have subscribed for a
total of 14,333,332 Placing Shares (the "Participating Directors"),
representing an aggregate amount of £2.15 million, as set out below:

 

 Director            Number of Placing Shares subscribed for  Shareholding following Admission  Percentage shareholding of enlarged issued share capital on Admission (%)
 Kevin Crofton       13,333,333                               18,780,749                        4.18
 Craig Gulliford(1)  333,333                                  2,043,635                         0.46
 Richard Rees        666,666                                  3,398,329                         0.76

 

(1) via a self-invested personal pension

 

Further detail on the Directors' participations, required in accordance with
UK MAR, is set out at the end of this Announcement.

 

The participation of each of the Participating Directors in the Placing in
aggregate constitutes a related party transaction pursuant to Rule 13 of the
AIM Rules for Companies. The independent directors for the purposes of Rule 13
of the AIM Rules (being Ivonne Cantu and Brent Boucher), having consulted with
Deutsche Numis, the Company's nominated adviser, consider the terms of the
related party transaction to be fair and reasonable insofar as shareholders of
the Company are concerned.

 

Admission, settlement and dealings

 

Application has been made to the London Stock Exchange for the Placing Shares
to be admitted to trading on the AIM market of the London Stock Exchange
("Admission").

 

Admission is expected to take place at 8.00 a.m. on 28 May 2026 and dealings
in the Placing Shares are expected to commence at 8.00 a.m. on 28 May 2026 or,
in each case, such later time and/or date as the Bookrunner and the Company
agree (being in any event no later than 8.00 a.m. on 9 June 2026).

 

The Placing Shares, when issued, will be credited as fully paid and will rank
pari passu in all respects with the Existing Ordinary Shares, including the
right to receive all dividends and other distributions declared, made or paid
after the date of issue.

 

Total voting rights

 

Following Admission, the total issued capital of the Company will consist
of 449,139,983 Ordinary Shares with voting rights. The Company does not hold
any Ordinary Shares in treasury. Therefore, the total number of voting rights
in the Company following Admission will be 449,139,983 and this figure may be
used by shareholders in the Company as the denominator for the calculations by
which they will determine if they are required to notify their interest in, or
a change to their interest in, the share capital of the Company under the
FCA's Disclosure Guidance and Transparency Rules.

 

The person responsible for arranging the release of this Announcement on
behalf of the Company is Richard Rees, a Director of the Company.

 

For further information, please contact:

 

 Creo Medical Group plc                               www.creomedical.com

                                                    (https://protect.checkpoint.com/v2/r02/___http:/www.creomedical.com___.YXAxZTpzaG9yZWNhcDpjOm86MmNhNDZiZWM4YWFkOGNhOTE1NTc4ZDNmODZjODI2MmY6NzoxY2FlOjI5ODQ3MGNjYzljNThiNWQyMzE0NzkwYjUwODhhYTI2ZDNjN2YwMzM2ZDQ3MzgyMjBkN2VmMmU3NzMzYThjN2M6cDpUOk4)
 Richard Craven, Company Secretary

                                                    Via Walbrook PR

 Deutsche Numis (Nominated Adviser and Joint Broker)  +44 (0)20 7545 8000

 Duncan Monteith / Sher Shah

 Shore Capital (Joint Broker and Sole Bookrunner)     +44 (0)20 7408 4090

 Daniel Bush / Lucy Bowden

 Walbrook PR Ltd                                      Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)

 Paul McManus / Alice Woodings                        Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/r02/___http:/www.creomedical.com___.YXAxZTpzaG9yZWNhcDpjOm86MmNhNDZiZWM4YWFkOGNhOTE1NTc4ZDNmODZjODI2MmY6NzoxY2FlOjI5ODQ3MGNjYzljNThiNWQyMzE0NzkwYjUwODhhYTI2ZDNjN2YwMzM2ZDQ3MzgyMjBkN2VmMmU3NzMzYThjN2M6cDpUOk4)
 

 

The information below (set out in accordance with the requirements of UK MAR)
provides further detail. PDMR Notification Forms:

 

 1    Details of the person discharging managerial responsibilities / person closely
      associated
 a)   Name                                                         1)    Kevin Crofton

                                                                   2)    Craig Gulliford

                                                                   3)    Richard Rees
 2    Reason for the notification
 a)   Position/status                                              1)    Chair

                                                                   2)    CEO

                                                                   3)    CFO
 b)   Initial notification /Amendment                                                           Initial Notification
 3    Details of the issuer, emission allowance market participant, auction
      platform, auctioneer or auction monitor
 a)   Name                                                                                      Creo Medical Group plc
 b)   LEI                                                                                       213800H188ZDCWWXFA21
 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted
 a)   Description of the financial instrument, type of instrument                               Ordinary Shares of 0.1 pence each
      Identification code                                                                       GB00BZ1BLL44

 b)   Nature of the transaction                                                                 1.    Purchase of Placing Shares

                                                                                                2.    Purchase of Placing Shares into a SIPP

                                                                                                3.    Purchase of Placing Shares
 c)   Price(s) and volume(s)                                                                    Price(s)  Volume(s)

                                                                                              1.  15p       13,333,333
                                                                                                2.  15p       333,333
                                                                                                3.  15p       666,666
 d)   Aggregated information

      Aggregate volume Price                                       N/A - single transactions

 e)   Date of the transaction                                      22 May 2026
 f)   Place of the transaction                                     AIM

d)

 

Aggregated information

Aggregate volume Price

 

N/A - single transactions

e)

Date of the transaction

22 May 2026

f)

Place of the transaction

AIM

 

 

Important Notices

 

Shore Capital is authorised and regulated by the Financial Conduct Authority
(the "FCA") in the United Kingdom and is acting exclusively for Creo and no
one else in connection with the Placing, and Shore Capital will not be
responsible to anyone (including any Placees) other than Creo for providing
the protections afforded to its clients or for providing advice in relation to
the Placing or any other matters referred to in this Announcement. No
representation or warranty, express or implied, is or will be made as to, or
in relation to, and no responsibility or liability is or will be accepted by
the Bookrunner or its Representatives as to, or in relation to, the accuracy
or completeness of this Announcement or any other written or oral information
made available to or publicly available to any interested party or its
advisers, and any liability therefore is expressly disclaimed.

 

Deutsche Bank AG is a stock corporation (Aktiengesellschaft) incorporated
under the laws of the Federal Republic of Germany with its principal office in
Frankfurt am Main. It is registered with the local district court
(Amtsgericht) in Frankfurt am Main under No HRB 30000 and licensed to carry on
banking business and to provide financial services. The London branch of
Deutsche Bank AG (trading for these purposes as Deutsche Numis) ("Deutsche
Numis") is registered as a branch office in the register of companies for
England and Wales at Companies House (branch registration number BR000005)
with its registered branch office address and principal place of business at
21, Moorfields, London EC2Y 9DB. Deutsche Bank AG is subject to supervision by
the European Central Bank (ECB), Sonnemannstrasse 22, 60314 Frankfurt am Main,
Germany, and the German Federal Financial Supervisory Authority (Bundesanstalt
für Finanzdienstleistungsaufsicht or BaFin), Graurheindorfer Strasse 108,
53117 Bonn and Marie-Curie-Strasse 24-28, 60439 Frankfurt am Main, Germany.
With respect to activities undertaken in the United Kingdom, Deutsche Bank AG
is authorised by the Prudential Regulation Authority (the "PRA"). It is
subject to regulation by the FCA and limited regulation by the PRA. Details
about the extent of Deutsche Bank AG's authorisation and regulation by the PRA
are available from Deutsche Bank AG on request. Deutsche Numis is acting as
nominated adviser to the Company and no other person in connection with the
contents of this Announcement and will not be responsible to any person other
than the Company for providing the protections afforded to clients of Deutsche
Numis, nor for providing advice in relation to any matters referred to herein.
The responsibilities of Deutsche Numis as Creo's nominated adviser under the
AIM Rules for Nominated Advisers are owed solely to the London Stock Exchange
and are not owed to Creo or to any Director or to any other person.

 

Certain statements in this Announcement are forward-looking statements which
are based on the Company's expectations, intentions and projections regarding
its future performance, anticipated events or trends and other matters that
are not historical facts. These forward-looking statements, which may use
words such as "aim", "anticipate", "believe", "intend", "estimate", "expect"
and words of similar meaning, include all matters that are not historical
facts. These forward-looking statements involve risks, assumptions and
uncertainties that could cause the actual results of operations, financial
condition, liquidity and dividend policy and the development of the industries
in which the Company's businesses operate to differ materially from the
impression created by the forward-looking statements. These statements are not
guarantees of future performance and are subject to known and unknown risks,
uncertainties and other factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements.
Given those risks and uncertainties, prospective investors are cautioned not
to place undue reliance on forward-looking statements.

 

The Placing Shares to be issued pursuant to the Placing will be not be
admitted to trading on any stock exchange other than the AIM market of the
London Stock Exchange.

 

The Placing Shares have not been approved or disapproved by the US Securities
and Exchange Commission, any state securities commission or other regulatory
authority in the United States, nor have any of the foregoing authorities
passed upon or endorsed the merits of the Placing or the accuracy or adequacy
of this Announcement. Any representation to the contrary is a criminal offence
in the United States. The relevant clearances have not been, nor will they be,
obtained from the securities commission of any province or territory of
Canada, no prospectus has been lodged with, or registered by, the Australian
Securities and Investments Commission or the Japanese Ministry of Finance; the
relevant clearances have not been, and will not be, obtained from the South
Africa Reserve Bank or any other applicable body in the Republic of South
Africa in relation to the Placing Shares; and the Placing Shares have not
been, nor will they be, registered under or offered in compliance with the
securities laws of any state, province or territory of the United States,
Australia, Canada, the Republic of South Africa or Japan. Accordingly, the
Placing Shares may not (unless an exemption under the relevant securities laws
is applicable) be offered, sold, resold or delivered, directly or indirectly,
in or into the United States, Australia, Canada, the Republic of South Africa
or Japan or any other jurisdiction outside the United Kingdom or the EEA.

 

Neither the content of Creo's website nor any website accessible by hyperlinks
on Creo's website is incorporated in, or forms part of, this Announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROIGZGZKLZRGVZG



            Copyright 2019 Regulatory News Service, all rights reserved